Kilter Group’s Amicus Therapeutics FOLD Stock Holding History

Kilter Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.46K	Buy	170 +39	+30%	+$559	﹤0.01%	876
2025 Q4	$1.87K	Buy	+131	New	+$1.29K	﹤0.01%	818

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Kilter Group's FOLD Position: Q1 2026 in Review

Kilter Group increased its Amicus Therapeutics (FOLD) stake by 30% in Q1 2026, buying an estimated $559 and bringing the position to 170 shares worth $2.46K. The position accounts for ﹤0.01% of the portfolio, ranked #876.

Kilter Group first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Kilter Group held 170 shares of Amicus Therapeutics worth $2.46K as of Q1 2026.
Kilter Group bought 39 Amicus Therapeutics shares in Q1 2026, an estimated $559.
Amicus Therapeutics made up ﹤0.01% of Kilter Group's portfolio in Q1 2026, its #876 holding.
Kilter Group first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Kilter Group's 13F filing for Q1 2026, filed 14 May 2026.